export const allDrugs = [
{
    name: "Irinotecan",
    dci: "irinotécan",
    commercial: "Campto",
    administration: "IV",
    class: "Topoisomerases 1 inhibitors",
    category: "chemotherapy",
    halfLife: "14h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[185]"
  },
  {
    name: "Topotecan",
    dci: "topotécan",
    commercial: "Hycamtin",
    administration: "IV, Oral",
    class: "Topoisomerases 1 inhibitors",
    category: "chemotherapy",
    halfLife: "5h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[185]"
  },
  {
    name: "Daunorubicine",
    dci: "daunorubicine",
    commercial: "Cerubidine",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[162]"
  },
  {
    name: "Doxorubicine",
    dci: "doxorubicine",
    commercial: "Adriamycine",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "3 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[162]"
  },
  {
    name: "Epirubicine",
    dci: "épirubicine",
    commercial: "Farmorubicine",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "20 to 40h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[162]"
  },
  {
    name: "Idarubicine",
    dci: "idarubicine",
    commercial: "Zavedos",
    administration: "IV",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "11 to 25h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[162]"
  },
  {
    name: "Etoposide",
    dci: "étoposide",
    commercial: "Vepeside, Celltop",
    administration: "IV, Oral",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "4 to 11h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[125]"
  },
  {
    name: "Bleomycine",
    dci: "bléomycine",
    commercial: "Bléomycine",
    administration: "IV, IM, SC",
    class: "Topoisomerases 2 inhibitors",
    category: "chemotherapy",
    halfLife: "4h",
    normofractionatedRT: "0 (except thoracic irradiation : 48h)",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[186,187]"
  },

  // Purine analogues
{
  name: "Mercaptopurine",
  dci: "mercaptopurine",
  commercial: "Purinethol",
  administration: "Oral",
  class: "Purine analogues",
  category: "chemotherapy",
  halfLife: "2h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[194]"
},
{
  name: "Fludarabine",
  dci: "fludarabine",
  commercial: "Fludara",
  administration: "IV, Oral",
  class: "Purine analogues",
  category: "chemotherapy",
  halfLife: "15 to 23h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days",
  references: "[195,196]"
},
{
  name: "Clofarabine",
  dci: "clofarabine",
  commercial: "Evoltra",
  administration: "IV",
  class: "Purine analogues",
  category: "chemotherapy",
  halfLife: "5.2h",
  normofractionatedRT: "3 days",
  palliativeRT: "3 days",
  stereotacticRT: "3 days",
  intracranialRT: "3 days",
  references: "[197,198]"
},
// Alkylating agents - Platinum based drugs
{
  name: "Cisplatin",
  dci: "cisplatine",
  commercial: "Cisplatine",
  administration: "IV",
  class: "Platinum based drugs",
  category: "chemotherapy",
  halfLife: "30 min",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Carboplatin",
  dci: "carboplatine",
  commercial: "Paraplatine",
  administration: "IV",
  class: "Platinum based drugs",
  category: "chemotherapy",
  halfLife: "6h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Oxaliplatine",
  dci: "oxaliplatine",
  commercial: "Eloxatine",
  administration: "IV",
  class: "Platinum based drugs",
  category: "chemotherapy",
  halfLife: "25min",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},

// Alkylating agents - Nitrogen mustards
{
  name: "Chlorambucil",
  dci: "chlorambucil",
  commercial: "Leukeran",
  administration: "Oral",
  class: "Nitrogen mustards",
  category: "chemotherapy",
  halfLife: "1.5h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[199]"
},
{
  name: "Melphalan",
  dci: "melphalan",
  commercial: "Alkeran",
  administration: "IV, Oral",
  class: "Nitrogen mustards",
  category: "chemotherapy",
  halfLife: "1.5h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[200]"
},
{
  name: "Cyclophosphamide",
  dci: "cyclophosphamide",
  commercial: "Endoxan",
  administration: "IV, Oral",
  class: "Nitrogen mustards",
  category: "chemotherapy",
  halfLife: "4 to 8h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[201,202]"
},
{
  name: "Ifosfamide",
  dci: "ifosfamide",
  commercial: "Holoxan",
  administration: "IV",
  class: "Nitrogen mustards",
  category: "chemotherapy",
  halfLife: "4 to 8h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[203,204]"
},
  // Anti metabolites agents
  {
    name: "5-Fluorouracil",
    dci: "fluorouracile",
    commercial: "Fluorouracile",
    administration: "IV",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "6min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0"
  },
  {
    name: "Capecitabine",
    dci: "capécitabine",
    commercial: "Xeloda",
    administration: "Oral",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "3h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0"
  },
  {
    name: "Triflurifine",
    dci: "trifluridine",
    commercial: "Lonsurf (avec tipiracil)",
    administration: "Oral",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "1.4h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[188,189]"
  },
  {
    name: "Tipiracil",
    dci: "tipiracil",
    commercial: "Lonsurf (avec trifluridine)",
    administration: "Oral",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "1.4h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[188,189]"
  },
{
    name: "Gemcitabine",
    dci: "gemcitabine",
    commercial: "Gemzar",
    administration: "IV",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "5 to 11h",
    normofractionatedRT: "7 days (except concurrent chemoradiation 100mg/m2)",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "0",
    references: "[190]"
  },
  {
    name: "Cytarabine",
    dci: "cytarabine",
    commercial: "Aracytine",
    administration: "IV, SC, IT",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "2h",
    normofractionatedRT: "2 days",
    palliativeRT: "2 days",
    stereotacticRT: "2 days",
    intracranialRT: "2 days",
    references: "[191]"
  },
  {
    name: "Azacitidine",
    dci: "azacitidine",
    commercial: "Vidaza",
    administration: "SC, IV",
    class: "Pyrimidine analogues",
    category: "chemotherapy",
    halfLife: "45min",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0"
  },
  {
    name: "Methotrexate",
    dci: "méthotrexate",
    commercial: "Methotrexate",
    administration: "Oral, IV, IM, IT",
    class: "Antifolates",
    category: "chemotherapy",
    halfLife: "8 to 15h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[164]"
  },
  {
    name: "Pemetrexed",
    dci: "pémétrexed",
    commercial: "Alimta",
    administration: "IV",
    class: "Antifolates",
    category: "chemotherapy",
    halfLife: "3.5h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[192]"
  },
  {
    name: "Ralitrexed",
    dci: "raltitrexed",
    commercial: "Tomudex",
    administration: "IV",
    class: "Antifolates",
    category: "chemotherapy",
    halfLife: "8 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[193]"
  },
  // Alkylating agents - Nitrosea urea
{
  name: "Bendamustine",
  dci: "bendamustine",
  commercial: "Levact, Bendeka",
  administration: "IV",
  class: "Nitrosea urea",
  category: "chemotherapy",
  halfLife: "30min",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[205,206]"
},
{
  name: "Fotemustine",
  dci: "fotémustine",
  commercial: "Muphoran",
  administration: "IV",
  class: "Nitrosea urea",
  category: "chemotherapy",
  halfLife: "30min to 2h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Lomustine",
  dci: "lomustine",
  commercial: "Bélustine",
  administration: "Oral",
  class: "Nitrosea urea",
  category: "chemotherapy",
  halfLife: "3 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[207,208]"
},

// Alcaloid
{
  name: "Trabectidine",
  dci: "trabectédine",
  commercial: "Yondelis",
  administration: "IV",
  class: "Alcaloid",
  category: "chemotherapy",
  halfLife: "7.5 days",
  normofractionatedRT: "5 days",
  palliativeRT: "0",
  stereotacticRT: "5 days",
  intracranialRT: "5 days",
  references: "[209,210]"
},

// Various
{
  name: "Dacarbazine",
  dci: "dacarbazine",
  commercial: "Déticène",
  administration: "IV",
  class: "Various",
  category: "chemotherapy",
  halfLife: "1.5h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h"
},
{
  name: "Procarbazine",
  dci: "procarbazine",
  commercial: "Natulan",
  administration: "Oral",
  class: "Various",
  category: "chemotherapy",
  halfLife: "7 min",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Mitomycin C",
  dci: "mitomycine",
  commercial: "Amétycine",
  administration: "IV, Intravésical",
  class: "Various",
  category: "chemotherapy",
  halfLife: "1h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Temozolomide",
  dci: "témozolomide",
  commercial: "Temodal",
  administration: "Oral, IV",
  class: "Various",
  category: "chemotherapy",
  halfLife: "1.8h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},

// Antimitutic agents - Taxanes
{
  name: "Paclitaxel",
  dci: "paclitaxel",
  commercial: "Taxol",
  administration: "IV",
  class: "Taxanes",
  category: "chemotherapy",
  halfLife: "24h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Nab-Paclitaxel",
  dci: "paclitaxel (nanoparticules d'albumine)",
  commercial: "Abraxane",
  administration: "IV",
  class: "Taxanes",
  category: "chemotherapy",
  halfLife: "24h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Docetaxel",
  dci: "docétaxel",
  commercial: "Taxotère",
  administration: "IV",
  class: "Taxanes",
  category: "chemotherapy",
  halfLife: "11h",
  normofractionatedRT: "2 days",
  palliativeRT: "2 days",
  stereotacticRT: "2 days",
  intracranialRT: "2 days"
},
{
  name: "Cabazitaxel",
  dci: "cabazitaxel",
  commercial: "Jevtana",
  administration: "IV",
  class: "Taxanes",
  category: "chemotherapy",
  halfLife: "96h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
// Antimitutic agents - Halichondrins
{
  name: "Eribuline",
  dci: "éribuline",
  commercial: "Halaven",
  administration: "IV",
  class: "Halichondrins",
  category: "chemotherapy",
  halfLife: "40h",
  normofractionatedRT: "5 days",
  palliativeRT: "0",
  stereotacticRT: "5 days",
  intracranialRT: "0",
  references: "[211]"
},
// Antimitutic agents - Vinca alkaloids
{
  name: "Vinblastine",
  dci: "vinblastine",
  commercial: "Velbé",
  administration: "IV",
  class: "Vinca alkaloids",
  category: "chemotherapy",
  halfLife: "24h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Vincristine",
  dci: "vincristine",
  commercial: "Oncovin",
  administration: "IV",
  class: "Vinca alkaloids",
  category: "chemotherapy",
  halfLife: "3.5 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[212]"
},
{
  name: "Vinorelbine",
  dci: "vinorelbine",
  commercial: "Navelbine",
  administration: "IV, Oral",
  class: "Vinca alkaloids",
  category: "chemotherapy",
  halfLife: "40h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[213,214]"
},
  // Endocrine Therapy - LH-RH agonists & antagonists
{
  name: "Goserelin",
  dci: "goséréline",
  commercial: "Zoladex",
  administration: "SC (implant)",
  class: "LH-RH agonists",
  category: "endocrine",
  halfLife: "7h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Leuproprelin",
  dci: "leuproréline",
  commercial: "Eligard, Enantone",
  administration: "SC, IM",
  class: "LH-RH agonists",
  category: "endocrine",
  halfLife: "3h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Triptoreline",
  dci: "triptoréline",
  commercial: "Décapeptyl",
  administration: "IM, SC",
  class: "LH-RH agonists",
  category: "endocrine",
  halfLife: "5h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Degarelix",
  dci: "dégarélix",
  commercial: "Firmagon",
  administration: "SC",
  class: "LH-RH antagonists",
  category: "endocrine",
  halfLife: "28 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Relugolix",
  dci: "rélugolix",
  commercial: "Orgovyx, Relumina",
  administration: "Oral",
  class: "LH-RH antagonists",
  category: "endocrine",
  halfLife: "61.5h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},

// Anti-androgens receptor
{
  name: "Bicalutamide",
  dci: "bicalutamide",
  commercial: "Casodex",
  administration: "Oral",
  class: "Anti-androgens receptor",
  category: "endocrine",
  halfLife: "7 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Apalutamide",
  dci: "apalutamide",
  commercial: "Erleada",
  administration: "Oral",
  class: "Anti-androgens receptor",
  category: "endocrine",
  halfLife: "72h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[215,216]"
},
{
  name: "Enzalutamide",
  dci: "enzalutamide",
  commercial: "Xtandi",
  administration: "Oral",
  class: "Anti-androgens receptor",
  category: "endocrine",
  halfLife: "6 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[217]"
},
{
  name: "Darolutamide",
  dci: "darolutamide",
  commercial: "Nubeqa",
  administration: "Oral",
  class: "Anti-androgens receptor",
  category: "endocrine",
  halfLife: "20h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[218]"
},

// Other endocrine therapies
{
  name: "Abiraterone acetate",
  dci: "acétate d'abiratérone",
  commercial: "Zytiga",
  administration: "Oral",
  class: "Cytochrome P450 C17 inhibitor",
  category: "endocrine",
  halfLife: "15h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[219,220]"
},
{
  name: "Tamoxifene",
  dci: "tamoxifène",
  commercial: "Nolvadex",
  administration: "Oral",
  class: "Anti estrogens receptor",
  category: "endocrine",
  halfLife: "7 days",
  normofractionatedRT: "0 (except radiosensibility)",
  palliativeRT: "0 (except radiosensibility)",
  stereotacticRT: "0 (except radiosensibility)",
  intracranialRT: "0 (except radiosensibility)",
  references: "[58]"
},
{
  name: "Fulvestrant",
  dci: "fulvestrant",
  commercial: "Faslodex",
  administration: "IM",
  class: "Anti estrogens receptor",
  category: "endocrine",
  halfLife: "50 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[221,222]"
},

// Anti-aromatases
{
  name: "Letrozole",
  dci: "létrozole",
  commercial: "Femara",
  administration: "Oral",
  class: "Anti-aromatases",
  category: "endocrine",
  halfLife: "2 to 4 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[223]"
},
{
  name: "Anastrozole",
  dci: "anastrozole",
  commercial: "Arimidex",
  administration: "Oral",
  class: "Anti-aromatases",
  category: "endocrine",
  halfLife: "48h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Exemestane",
  dci: "exémestane",
  commercial: "Aromasine",
  administration: "Oral",
  class: "Anti-aromatases",
  category: "endocrine",
  halfLife: "24h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
  // Targeted therapy drugs
  {
    name: "Alectinib",
    dci: "alectinib",
    commercial: "Alecensa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "32h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "0",
    references: "[286]"
  },
  {
    name: "Brigatinib",
    dci: "brigatinib",
    commercial: "Alunbrig",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "0"
  },
  {
    name: "Ceritinib",
    dci: "céritinib",
    commercial: "Zykadia",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "40h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "0"
  },
  {
    name: "Crizotinib",
    dci: "crizotinib",
    commercial: "Xalkori",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors",
    category: "targeted",
    halfLife: "42h",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
    references: "[225,226,227]"
  },
  {
  name: "Lorlatinib",
  dci: "lorlatinib",
  commercial: "Lorviqua",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (ALK)",
  category: "targeted",
  halfLife: "24h",
  normofractionatedRT: "5 days",
  palliativeRT: "0",
  stereotacticRT: "5 days",
  intracranialRT: "0"
},

// BCR-ABL inhibitors
{
  name: "Bosutinib",
  dci: "bosutinib",
  commercial: "Bosulif",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BCR-ABL)",
  category: "targeted",
  halfLife: "35h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Dasatinib",
  dci: "dasatinib",
  commercial: "Sprycel",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BCR-ABL)",
  category: "targeted",
  halfLife: "5h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[228,229]"
},
{
  name: "Imatinib",
  dci: "imatinib",
  commercial: "Glivec",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BCR-ABL)",
  category: "targeted",
  halfLife: "18h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days",
  references: "[230]"
},
{
  name: "Nilotinib",
  dci: "nilotinib",
  commercial: "Tasigna",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BCR-ABL)",
  category: "targeted",
  halfLife: "17h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days",
  references: "[231]"
},
{
  name: "Ponatinib",
  dci: "ponatinib",
  commercial: "Iclusig",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BCR-ABL)",
  category: "targeted",
  halfLife: "22h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},

// BTK inhibitors
{
  name: "Acalabrutinib",
  dci: "acalabrutinib",
  commercial: "Calquence",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BTK)",
  category: "targeted",
  halfLife: "7h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h"
},
{
  name: "Ibrutinib",
  dci: "ibrutinib",
  commercial: "Imbruvica",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BTK)",
  category: "targeted",
  halfLife: "4h to 13h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[232]"
},
{
  name: "Pirtobrutinib",
  dci: "pirtobrutinib",
  commercial: "Jaypirca",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (BTK)",
  category: "targeted",
  halfLife: "19h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
// EGFR inhibitors
{
  name: "Afatinib",
  dci: "afatinib",
  commercial: "Giotrif",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (EGFR)",
  category: "targeted",
  halfLife: "37h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "0",
  references: "[235]"
},
{
  name: "Gefitinib",
  dci: "géfitinib",
  commercial: "Iressa",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (EGFR)",
  category: "targeted",
  halfLife: "41h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[236]"
},
{
  name: "Erlotinib",
  dci: "erlotinib",
  commercial: "Tarceva",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (EGFR)",
  category: "targeted",
  halfLife: "36h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Osimertinib",
  dci: "osimertinib",
  commercial: "Tagrisso",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (EGFR)",
  category: "targeted",
  halfLife: "48h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[237,238]"
},

// Other specific inhibitors
{
  name: "Futibatinib",
  dci: "futibatinib",
  commercial: "Lytgobi",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (FGFR)",
  category: "targeted",
  halfLife: "3h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h"
},
{
  name: "Pemigatinib",
  dci: "pémigatinib",
  commercial: "Pemazyre",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (FGFR2)",
  category: "targeted",
  halfLife: "15h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Gilteritinib",
  dci: "giltéritinib",
  commercial: "Xospata",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (FLT3)",
  category: "targeted",
  halfLife: "4.7 days",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Lapatinib",
  dci: "lapatinib",
  commercial: "Tyverb",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (HER2)",
  category: "targeted",
  halfLife: "24h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[239,81]"
},
{
  name: "Tucatinib",
  dci: "tucatinib",
  commercial: "Tukysa",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (HER2)",
  category: "targeted",
  halfLife: "8.5h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[81]"
},

// JAK & MEK inhibitors
{
  name: "Fedratinib",
  dci: "fédratinib",
  commercial: "Inrebic",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (JAK)",
  category: "targeted",
  halfLife: "4.75 days",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Ruxolitinib",
  dci: "ruxolitinib",
  commercial: "Jakavi",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (JAK)",
  category: "targeted",
  halfLife: "3h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h"
},
{
  name: "Binimetinib",
  dci: "binimétinib",
  commercial: "Mektovi",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (MEK)",
  category: "targeted",
  halfLife: "8.66h",
  normofractionatedRT: "3 days",
  palliativeRT: "3 days",
  stereotacticRT: "3 days",
  intracranialRT: "3 days",
  references: "[178]"
},
// MET, RET and other inhibitors
{
  name: "Capmatinib",
  dci: "capmatinib",
  commercial: "Tabrecta",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (MET)",
  category: "targeted",
  halfLife: "6.5h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[240]"
},
{
  name: "Cabozantinib",
  dci: "cabozantinib",
  commercial: "Cabometyx, Cometriq",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (MET, RET, ROS1, VEGFR)",
  category: "targeted",
  halfLife: "4.5 days",
  normofractionatedRT: "21 days",
  palliativeRT: "0 (except abdominopelvic)",
  stereotacticRT: "21 days",
  intracranialRT: "0",
  references: "[241,242]"
},
{
  name: "Tepotinib",
  dci: "tépotinib",
  commercial: "Tepmetko",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (MET)",
  category: "targeted",
  halfLife: "32h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Selpercatinib",
  dci: "selpercatinib",
  commercial: "Retsevmo",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (RET fusion)",
  category: "targeted",
  halfLife: "24h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days"
},
{
  name: "Larotrectinib",
  dci: "larotrectinib",
  commercial: "Vitrakvi",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (TRK)",
  category: "targeted",
  halfLife: "3h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[243]"
},

// VEGFR inhibitors
{
  name: "Axitinib",
  dci: "axitinib",
  commercial: "Inlyta",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (VEGFR)",
  category: "targeted",
  halfLife: "2.5h to 6h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[244,245]"
},
{
  name: "Lenvatinib",
  dci: "lenvatinib",
  commercial: "Lenvima, Kisplyx",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (c-Kit, FGFR, PDGFR, VEGFR)",
  category: "targeted",
  halfLife: "28h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days",
  references: "[246,247]"
},
{
  name: "Sorafenib",
  dci: "sorafénib",
  commercial: "Nexavar",
  administration: "Oral",
  class: "Tyrosine kinase inhibitors (c-Kit, FLT3, PDGFR, VEGFR)",
  category: "targeted",
  halfLife: "24h to 48h",
  normofractionatedRT: "7 days",
  palliativeRT: "0 (except abdomino pelvic)",
  stereotacticRT: "7 days",
  intracranialRT: "0",
  references: "[170,248,249]"
},

// Monoclonal antibodies
{
  name: "Obinutuzumab",
  dci: "obinutuzumab",
  commercial: "Gazyvaro",
  administration: "IV",
  class: "Monoclonal antibodies (CD20)",
  category: "targeted",
  halfLife: "23.9 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[262]"
},
{
  name: "Rituximab",
  dci: "rituximab",
  commercial: "MabThera, Rituxan",
  administration: "IV, SC",
  class: "Monoclonal antibodies (CD20)",
  category: "targeted",
  halfLife: "22 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[263]"
},
{
  name: "Cetuximab",
  dci: "cétuximab",
  commercial: "Erbitux",
  administration: "IV",
  class: "Monoclonal antibodies (EGFR)",
  category: "targeted",
  halfLife: "4 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Bevacizumab",
  dci: "bévacizumab",
  commercial: "Avastin",
  administration: "IV",
  class: "Monoclonal antibodies (VEGFR)",
  category: "targeted",
  halfLife: "18 to 20 days",
  normofractionatedRT: "21 days",
  palliativeRT: "0 (except abdomino pelvic)",
  stereotacticRT: "21 days",
  intracranialRT: "0"
},
// Autres thérapies ciblées
{
  name: "Venetoclax",
  dci: "vénétoclax",
  commercial: "Venclyxto",
  administration: "Oral",
  class: "Bcl-2 inhibitors",
  category: "targeted",
  halfLife: "26h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[249]"
},
{
  name: "Dabrafenib",
  dci: "dabrafénib",
  commercial: "Tafinlar",
  administration: "Oral",
  class: "BRAF inhibitors",
  category: "targeted",
  halfLife: "2.6h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[178]"
},
{
  name: "Encorafenib",
  dci: "encorafénib",
  commercial: "Braftovi",
  administration: "Oral",
  class: "BRAF inhibitors",
  category: "targeted",
  halfLife: "6.3h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h"
},
{
  name: "Vemurafenib",
  dci: "vémurafénib",
  commercial: "Zelboraf",
  administration: "Oral",
  class: "BRAF inhibitors",
  category: "targeted",
  halfLife: "51h",
  normofractionatedRT: "7 days",
  palliativeRT: "7 days",
  stereotacticRT: "7 days",
  intracranialRT: "7 days"
},

// PARP inhibitors
{
  name: "Niraparib",
  dci: "niraparib",
  commercial: "Zejula",
  administration: "Oral",
  class: "PARP inhibitors",
  category: "targeted",
  halfLife: "48h",
  normofractionatedRT: "5 days",
  palliativeRT: "0",
  stereotacticRT: "5 days",
  intracranialRT: "0"
},
{
  name: "Olaparib",
  dci: "olaparib",
  commercial: "Lynparza",
  administration: "Oral",
  class: "PARP inhibitors",
  category: "targeted",
  halfLife: "15h",
  normofractionatedRT: "5 days",
  palliativeRT: "0",
  stereotacticRT: "5 days",
  intracranialRT: "0",
  references: "[184]"
},
{
  name: "Rucaparib",
  dci: "rucaparib",
  commercial: "Rubraca",
  administration: "Oral",
  class: "PARP inhibitors",
  category: "targeted",
  halfLife: "26h",
  normofractionatedRT: "5 days",
  palliativeRT: "0",
  stereotacticRT: "5 days",
  intracranialRT: "0"
},

// Proteasome inhibitors et autres
{
  name: "Bortezomib",
  dci: "bortézomib",
  commercial: "Velcade",
  administration: "IV, SC",
  class: "Proteasome inhibitors",
  category: "targeted",
  halfLife: "40 to 193h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[254,255,256]"
},
{
  name: "Carfilzomib",
  dci: "carfilzomib",
  commercial: "Kyprolis",
  administration: "IV",
  class: "Proteasome inhibitors",
  category: "targeted",
  halfLife: "1h",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},

// Immunomodulators
{
  name: "Lenalidomide",
  dci: "lénalidomide",
  commercial: "Revlimid",
  administration: "Oral",
  class: "Immunomodulators",
  category: "immunotherapy",
  halfLife: "3h to 5h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[267,268]"
},
{
  name: "Pomalidomide",
  dci: "pomalidomide",
  commercial: "Imnovid",
  administration: "Oral",
  class: "Immunomodulators",
  category: "immunotherapy",
  halfLife: "9h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[264]"
},
{
  name: "Thalidomide",
  dci: "thalidomide",
  commercial: "Thalidomide",
  administration: "Oral",
  class: "Immunomodulators",
  category: "immunotherapy",
  halfLife: "7h",
  normofractionatedRT: "48h",
  palliativeRT: "48h",
  stereotacticRT: "48h",
  intracranialRT: "48h",
  references: "[269,270,271]"
},

// Antibody-drug conjugates
{
  name: "Brentuximab vedotin",
  dci: "brentuximab védotine",
  commercial: "Adcetris",
  administration: "IV",
  class: "Antibody-drug conjugates (CD30)",
  category: "targeted",
  halfLife: "4 to 6 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[275,276]"
},
{
  name: "Trastuzumab Emtansine",
  dci: "trastuzumab emtansine",
  commercial: "Kadcyla",
  administration: "IV",
  class: "Antibody-drug conjugates (HER2)",
  category: "targeted",
  halfLife: "4 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[81]"
},
// Derniers anticorps monoclonaux et protéines de fusion
{
  name: "Ramucirumab",
  dci: "ramucirumab",
  commercial: "Cyramza",
  administration: "IV",
  class: "Monoclonal antibodies (VEGFR)",
  category: "targeted",
  halfLife: "14 days",
  normofractionatedRT: "21days",
  palliativeRT: "0 (except abdomino pelvic)",
  stereotacticRT: "21days",
  intracranialRT: "0",
  references: "[265,266]"
},
{
  name: "Aflibercept",
  dci: "aflibercept",
  commercial: "Zaltrap",
  administration: "IV",
  class: "Recombinant fusion protein (VEGF)",
  category: "targeted",
  halfLife: "6 days",
  normofractionatedRT: "21days",
  palliativeRT: "0 (except abdomino pelvic)",
  stereotacticRT: "21days",
  intracranialRT: "0"
},
// Antibody-drug conjugates
{
  name: "Trastuzumab Deruxtecan",
  dci: "trastuzumab déruxtécan",
  commercial: "Enhertu",
  administration: "IV",
  class: "Antibody-drug conjugates",
  category: "targeted",
  halfLife: "7 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[277]"
},
{
  name: "Enfortumab Vedotin",
  dci: "enfortumab védotine",
  commercial: "Padcev",
  administration: "IV",
  class: "Antibody-drug conjugates (Nectin 4)",
  category: "targeted",
  halfLife: "3.6 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0",
  references: "[278,279]"
},
{
  name: "Sacituzumab govitecan",
  dci: "sacituzumab govitécan",
  commercial: "Trodelvy",
  administration: "IV",
  class: "Antibody-drug conjugates (TROP2)",
  category: "targeted",
  halfLife: "15h to 19h",
  normofractionatedRT: "5 days",
  palliativeRT: "5 days",
  stereotacticRT: "5 days",
  intracranialRT: "5 days",
  references: "[280]"
},

// Immunotherapy drugs
{
  name: "Nivolumab",
  dci: "nivolumab",
  commercial: "Opdivo",
  administration: "IV",
  class: "PD1 inhibitors",
  category: "immunotherapy",
  halfLife: "25 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Pembrolizumab",
  dci: "pembrolizumab",
  commercial: "Keytruda",
  administration: "IV",
  class: "PD1 inhibitors",
  category: "immunotherapy",
  halfLife: "22 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Atezolizumab",
  dci: "atézolizumab",
  commercial: "Tecentriq",
  administration: "IV",
  class: "PDL1 inhibitors",
  category: "immunotherapy",
  halfLife: "27 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Avelumab",
  dci: "avélumab",
  commercial: "Bavencio",
  administration: "IV",
  class: "PDL1 inhibitors",
  category: "immunotherapy",
  halfLife: "6 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Durvalumab",
  dci: "durvalumab",
  commercial: "Imfinzi",
  administration: "IV",
  class: "PDL1 inhibitors",
  category: "immunotherapy",
  halfLife: "18 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Ipilimumab",
  dci: "ipilimumab",
  commercial: "Yervoy",
  administration: "IV",
  class: "CTLA4 inhibitors",
  category: "immunotherapy",
  halfLife: "15 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
  name: "Tremelimumab",
  dci: "trémélimumab",
  commercial: "Imjudo",
  administration: "IV",
  class: "CTLA4 inhibitors",
  category: "immunotherapy",
  halfLife: "14.2 days",
  normofractionatedRT: "0",
  palliativeRT: "0",
  stereotacticRT: "0",
  intracranialRT: "0"
},
{
    name: "Abemaciclib",
    dci: "abémaciclib",
    commercial: "Verzenios",
    administration: "Oral",
    class: "CDK4/6 inhibitors",
    category: "targeted",
    halfLife: "25h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[81]"
  },
  {
    name: "Palbociclib",
    dci: "palbociclib",
    commercial: "Ibrance",
    administration: "Oral",
    class: "CDK4/6 inhibitors",
    category: "targeted",
    halfLife: "29h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[81]"
  },
  {
    name: "Ribociclib",
    dci: "ribociclib",
    commercial: "Kisqali",
    administration: "Oral",
    class: "CDK4/6 inhibitors",
    category: "targeted",
    halfLife: "30 to 55h",
    normofractionatedRT: "5 days",
    palliativeRT: "0",
    stereotacticRT: "5 days",
    intracranialRT: "5 days"
  },
  {
    name: "Vorinostat",
    dci: "vorinostat",
    commercial: "Zolinza",
    administration: "Oral",
    class: "Histones deacetylases HDAC inhibitors",
    category: "targeted",
    halfLife: "2h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[250,251]"
  },
  {
    name: "Panobinostat",
    dci: "panobinostat",
    commercial: "Farydak",
    administration: "Oral",
    class: "CDK4/6 inhibitors, IDH-1 inhibitors, IDH-2 inhibitors",
    category: "targeted",
    halfLife: "37h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[252]"
  },
{
    name: "Panobinostat",
    dci: "panobinostat",
    commercial: "Farydak",
    administration: "Oral",
    class: "CDK4/6 inhibitors, IDH-1 inhibitors, IDH-2 inhibitors",
    category: "targeted",
    halfLife: "37h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[252]"
  },
  {
    name: "Ivosidenib",
    dci: "ivosidénib",
    commercial: "Tibsovo",
    administration: "Oral",
    class: "Isocitrate dehydrogenase inhibitors (IDH-1)",
    category: "targeted",
    halfLife: "58h to 129h",
    normofractionatedRT: "0 days",
    palliativeRT: "0 days",
    stereotacticRT: "0 days",
    intracranialRT: "0 days",
    references: "[253]"
  },
  {
    name: "Enasidenib",
    dci: "énasidénib",
    commercial: "Idhifa",
    administration: "Oral",
    class: "Unspecified",
    category: "targeted",
    halfLife: "8 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days"
  },
  {
    name: "Adagrasib",
    dci: "adagrasib",
    commercial: "Krazati",
    administration: "Oral",
    class: "KRAS G12C inhibitors",
    category: "targeted",
    halfLife: "24h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days"
  },
  {
    name: "Sotorasib",
    dci: "sotorasib",
    commercial: "Lumykras",
    administration: "Oral",
    class: "KRAS G12C inhibitors",
    category: "targeted",
    halfLife: "5h",
    normofractionatedRT: "2 days",
    palliativeRT: "2 days",
    stereotacticRT: "2 days",
    intracranialRT: "2 days"
  },
  {
    name: "Niraparib",
    dci: "niraparib",
    commercial: "Zejula",
    administration: "Oral",
    class: "PARP inhibitors",
    category: "targeted",
    halfLife: "48h",
    normofractionatedRT: "5 days",
    palliativeRT: "0 days",
    stereotacticRT: "5 days",
    intracranialRT: "0 days"
  },
  {
    name: "Talazoparib",
    dci: "talazoparib",
    commercial: "Talzenna",
    administration: "Oral",
    class: "PARP inhibitors",
    category: "targeted",
    halfLife: "3.75 days",
    normofractionatedRT: "5 days",
    palliativeRT: "0 days",
    stereotacticRT: "5 days",
    intracranialRT: "0 days"
  },
  {
    name: "Ixazomib",
    dci: "ixazomib",
    commercial: "Ninlaro",
    administration: "Oral",
    class: "Proteasome inhibitors",
    category: "targeted",
    halfLife: "9.5 days",
    normofractionatedRT: "0 days",
    palliativeRT: "0 days",
    stereotacticRT: "0 days",
    intracranialRT: "0 days"
  },
  {
    name: "Vismodegib",
    dci: "vismodégib",
    commercial: "Erivedge",
    administration: "Oral",
    class: "SMO protein inhibitors",
    category: "targeted",
    halfLife: "4 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[257, 258]"
  },
  {
    name: "Sonidegib",
    dci: "sonidégib",
    commercial: "Odomzo",
    administration: "Oral",
    class: "Proteasome inhibitors, PI3K inhibitors",
    category: "targeted",
    halfLife: "28 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[259]"
  },
  {
    name: "Daratumumab",
    dci: "daratumumab",
    commercial: "Darzalex",
    administration: "IV, SC",
    class: "PI3K inhibitors (CD38)",
    category: "targeted",
    halfLife: "9 days",
    normofractionatedRT: "0 days",
    palliativeRT: "0 days",
    stereotacticRT: "0 days",
    intracranialRT: "0 days",
    references: "[264]"
  },
  {
    name: "Pertuzumab",
    dci: "pertuzumab",
    commercial: "Perjeta",
    administration: "IV",
    class: "Monoclonal antibodies (HER2)",
    category: "targeted",
    halfLife: "18 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
  },
  {
    name: "Trastuzumab",
    dci: "trastuzumab",
    commercial: "Herceptin",
    administration: "IV, SC",
    class: "Monoclonal antibodies (HER2)",
    category: "targeted",
    halfLife: "28.5 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0",
  },
  {
    name: "Zanubrutinib",
    dci: "zanubrutinib",
    commercial: "Brukinsa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (BTK)",
    category: "targeted",
    halfLife: "4h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h"
  },
  {
    name: "Pazopanib",
    dci: "pazopanib",
    commercial: "Votrient",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (c-Kit)",
    category: "targeted",
    halfLife: "31h",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[233, 234]"
  },
  {
    name: "Ripretinib",
    dci: "riprétinib",
    commercial: "Qinlock",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (c-Kit)",
    category: "targeted",
    halfLife: "15h",
    normofractionatedRT: "3 days",
    palliativeRT: "3 days",
    stereotacticRT: "3 days",
    intracranialRT: "3 days"
  },
  {
    name: "Cobimetinib",
    dci: "cobimétinib",
    commercial: "Cotellic",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MEK)",
    category: "targeted",
    halfLife: "43h",
    normofractionatedRT: "10 days",
    palliativeRT: "10 days",
    stereotacticRT: "10 days",
    intracranialRT: "10 days"
  },
  {
    name: "Trametinib",
    dci: "tramétinib",
    commercial: "Mekinist",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (MEK)",
    category: "targeted",
    halfLife: "127h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h"
  },
  {
    name: "Alpelisib",
    dci: "alpélisib",
    commercial: "Piqray",
    administration: "Oral",
    class: "PI3K inhibitors",
    category: "targeted",
    halfLife: "9h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[260]"
  },
  {
    name: "Idelalisib",
    dci: "idélalisib",
    commercial: "Zydelig",
    administration: "Oral",
    class: "PI3K inhibitors",
    category: "targeted",
    halfLife: "8h",
    normofractionatedRT: "48h",
    palliativeRT: "48h",
    stereotacticRT: "48h",
    intracranialRT: "48h",
    references: "[261]"
  },
  {
    name: "Everolimus",
    dci: "évérolimus",
    commercial: "Afinitor",
    administration: "Oral",
    class: "Immunosuppressors",
    category: "targeted",
    halfLife: "30h",
    normofractionatedRT: "7 days",
    palliativeRT: "7 days",
    stereotacticRT: "7 days",
    intracranialRT: "7 days",
    references: "[273, 274, 272]"
  },
  {
    name: "Panitumumab",
    dci: "panitumumab",
    commercial: "Vectibix",
    administration: "IV",
    class: "Monoclonal antibodies (EGFR)",
    category: "targeted",
    halfLife: "7 days",
    normofractionatedRT: "0",
    palliativeRT: "0",
    stereotacticRT: "0",
    intracranialRT: "0"
  },
  {
    name: "Vandetanib",
    dci: "vandétanib",
    commercial: "Caprelsa",
    administration: "Oral",
    class: "Tyrosine kinase inhibitors (EGFR, VEGFR)",
    category: "targeted",
    halfLife: "19 days",
    normofractionatedRT: "5 days",
    palliativeRT: "5 days",
    stereotacticRT: "5 days",
    intracranialRT: "5 days",
    references: "[228]"
  }
];